Lasa Supergenerics (540702) Stock Overview
Engages in the research, manufacture, and marketing of animal and human healthcare products in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
540702 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Lasa Supergenerics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹10.25 |
| 52 Week High | ₹33.49 |
| 52 Week Low | ₹8.52 |
| Beta | 0.17 |
| 1 Month Change | -11.33% |
| 3 Month Change | -39.78% |
| 1 Year Change | -57.38% |
| 3 Year Change | -73.45% |
| 5 Year Change | -83.92% |
| Change since IPO | -93.03% |
Recent News & Updates
Recent updates
Shareholder Returns
| 540702 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -5.6% | 0.4% | -1.9% |
| 1Y | -57.4% | 4.6% | -6.4% |
Return vs Industry: 540702 underperformed the Indian Pharmaceuticals industry which returned 4.6% over the past year.
Return vs Market: 540702 underperformed the Indian Market which returned -6.4% over the past year.
Price Volatility
| 540702 volatility | |
|---|---|
| 540702 Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in IN Market | 8.2% |
| 10% least volatile stocks in IN Market | 3.7% |
Stable Share Price: 540702's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 540702's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 77 | Omkar Herlekar | lasalabs.com |
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, and halquinol, as well as 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, such as potassium iodide.
Lasa Supergenerics Limited Fundamentals Summary
| 540702 fundamental statistics | |
|---|---|
| Market cap | ₹518.05m |
| Earnings (TTM) | -₹147.57m |
| Revenue (TTM) | ₹1.47b |
Is 540702 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 540702 income statement (TTM) | |
|---|---|
| Revenue | ₹1.47b |
| Cost of Revenue | ₹1.06b |
| Gross Profit | ₹412.73m |
| Other Expenses | ₹560.30m |
| Earnings | -₹147.57m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.95 |
| Gross Margin | 27.99% |
| Net Profit Margin | -10.01% |
| Debt/Equity Ratio | 2.5% |
How did 540702 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/01 14:25 |
| End of Day Share Price | 2025/08/01 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lasa Supergenerics Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.